Gene group for breast cancer molecular typing, detection product and application thereof
A molecular typing and breast cancer technology, applied in the biological field, can solve problems such as physical injury of patients, and achieve the effect of alleviating pain and avoiding injury.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0030] Example 1 There are significant differences in sEVs proteins in patients with four subtypes of breast cancer
[0031] The present invention takes plasma from 20 patients with lumen A breast cancer, 50 patients with lumen B type, 21 patients with HER2 enrichment type and 23 patients with triple negative breast cancer, and extracts the sEVs protein in the plasma. The extracted sEVs proteins were analyzed by UHPLC-QExactive HF MS to separate and identify which sEVs proteins were expressed in each of the above four subtypes, and to obtain the expression abundance of each protein. Furthermore, in order to detect whether there are differences in the sEVs proteins in the four subtypes of people, so that these sEVs proteins can be used for molecular typing, the present invention further performs PCA analysis on these sEVs proteins.
[0032] 1. Experimental method
[0033] 1. sEVs protein extraction
[0034] (1) Differential ultracentrifugation purification of sEVs: First, 1 m...
Embodiment 2
[0045] Example 2 Obtaining significantly differentially expressed sEVs proteins in patients of each subtype
[0046] Further, the present invention obtains significantly differentially expressed sEVs proteins in patients of each subtype through t-test and nominal p-value cutoff (p<0.05) analysis.
[0047] 1. Experimental method
[0048] t-test and nominal p-value cut-off (p<0.05) analysis: 1924 specifically expressed sEVs proteins were analyzed by t-test, and the sEVs proteins that were significantly differentially expressed in breast cancer patients were determined by calculating the fold difference. The determination method is:
[0049] Fold difference = the amount of the protein expressed in one of the subtypes of breast cancer patients / the amount of the protein expressed in the other subtypes of patients
[0050] If the multiples of difference are all greater than 2, it is considered that the protein is significantly differentially expressed in the breast cancer subtype ...
Embodiment 3
[0053] Example 3 Construction of breast cancer subtype typing model
[0054] Based on the above-mentioned 356 significantly differentially expressed sEVs proteins, the present invention adopts the XGBoost classification method to construct a subtype model of breast cancer, in order to obtain a model capable of molecular typing of breast cancer. It prevents tissue biopsy from harming the patient's body and reduces the patient's pain in seeing a doctor.
[0055] 1. Experimental method
[0056] The XGBoost classification method is an existing classification method that is robust to noise and overfitting. Based on the XGBoost classification method, the present invention imports the above-mentioned 356 significantly differentially expressed sEVs protein data into the XGBoost classification model, uses 70% of the samples of the above breast cancer subtypes as a training set, and the remaining 30% as an independent test set to carry out the model train.
[0057] 2. Experimental re...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


